Astrazeneca Ab

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Magnus Munck Af Rosenschöld

Matti Juhani Lepistö

Anders Eriksson

Michael Lundkvist

Pavol Zlatoidsky

Krister Henriksson

Balint Gabos

Hartmut Rehwinkel

Markus Berger

Darren Mckerrecher

Martin Hemmerling

Karl Henrik Edman

Stinabritt Nilsson

Svetlana Ivanova

Thomas Hansson

Antonios Nikitidis

Jan Dahmén

Camilla Taflin

David Chapman

Erik Ringberg

Hans Lönn

Grigorios Nikitidis

John Pavey

Petra Johannesson

Christian Tyrchan

Kristina Stenvall

Martin Lindsjö

Debra Ainge

Peter Nilsson

Wesley Ralph Schaal

Hanna Birgitta Ellinor Andersson

Carl Jonas Lindh

Matti Lepistö

Karl Edman

There is provided compounds of formula I, wherein E, E, E, E, L, Y, Y, Y, Rand z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene Csynthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.

Compounds and uses

The invention provides certain novel compounds as listed in the specification and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase. The present neutrophil elastase inhibitors include 6-[1-(4-Cyanophenyl)-1H-pyrazol-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide: 

Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase

The invention provides compounds of formula (I): 

Hydantoin compounds and pharmaceutical compositions thereof

Compounds of the formula (I) wherein Z is SO(N6) or N(R7)SOor N(R7)SON(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.

Metalloproteinase inhibitors

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

Chemical compounds 572

Compounds of the formula (I) wherein z is SOor SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.

The invention provides compounds of formula in which L, X, Y, Z, Z, R, R, Rand Ghave the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12

The invention provides compounds of formula (I) in which L, X, Y, Z, Z, R, R, Rand Ghave the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds of the invention are inhibitors of metalloproteinase MMP12 and are among other things useful for the treatment of obstructive airways diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12

Compounds of the formula (I), useful as metal-loproteinase inhibitors, especially as inhibitors of MMP12 

Growing community of inventors

Lund, Sweden

Magnus Munck Af Rosenschöld